Lartruvo
PHONETIC PRONUNCIATION: Lartruvo
Description
Lartruvo (olaratumab) is a medication used in the treatment of soft tissue sarcoma, a rare type of cancer that affects the body's connective tissues. This medication is classified as a monoclonal antibody, a type of medication that targets specific cancer cells and prevents their proliferation. Uses of Lartruvo Lartruvo is used in combination with the chemotherapy drug doxorubicin in the treatment of advanced soft tissue sarcoma that cannot be removed through surgery. It is intended for use in patients whose cancer has spread to other parts of the body. Dosage of Lartruvo Lartruvo is administered intravenously (through a vein) once every two weeks. The dosage is based on the patient's body weight, with a maximum dose of 20 mg/kg. Demographic Lartruvo is indicated for use in adult patients with advanced soft tissue sarcoma. Side Effects of Lartruvo The most common side effects associated with Lartruvo include nausea, fatigue, vomiting, low white blood cell count, low platelet count, and muscle pain. Less common but more serious side effects include infusion-related reactions such as fever, chills, and shortness of breath. Patients are monitored closely during the infusion process to prevent these reactions from occurring. Interactions Lartruvo has no known drug interactions. However, patients taking a blood thinner medication such as warfarin should inform their healthcare provider before starting treatment with Lartruvo. Generic Options Lartruvo is not currently available in a generic form. It is a brand-name medication manufactured and distributed by Eli Lilly and Company. Conclusion Lartruvo is an important medication used in the treatment of advanced soft tissue sarcoma. It is typically administered in combination with chemotherapy and has demonstrated efficacy in improving patient outcomes. Like any medication, Lartruvo does carry some risk of side effects and should only be used under the guidance of a qualified healthcare professional. Patients considering treatment with this medication should discuss its potential benefits and risks with their doctor to determine if it is an appropriate treatment option for their specific condition.
Faq for Lartruvo
Lartruvo (olaratumab) is a prescription medication used for the treatment of certain types of soft tissue sarcoma. It is typically administered in combination with doxorubicin, another chemotherapy drug.
Lartruvo belongs to a class of medications called monoclonal antibodies. It works by binding to a protein called platelet-derived growth factor receptor alpha (PDGFR-α), which is found in some types of cancer cells. By binding to this protein, Lartruvo helps to inhibit tumor growth and spread.
The most common side effects of Lartruvo include nausea, fatigue, muscle pain, joint pain, decreased appetite, vomiting, diarrhea, swelling in the hands or feet, and hair loss. It is important to note that individual experiences with side effects may vary.
Lartruvo is administered as an intravenous infusion by a healthcare professional. The infusion typically takes about one hour and is usually repeated every two weeks.
Before starting Lartruvo, it is important to inform your healthcare provider about any existing medical conditions, including allergies, liver or kidney problems, as well as any medications you are currently taking. Additionally, if you are pregnant, planning to become pregnant, or breastfeeding, you should discuss the potential risks and benefits of Lartruvo with your doctor.
The duration of Lartruvo treatment can vary depending on individual response, tolerability, and the recommendation of your healthcare provider. It is important to follow the specific treatment plan outlined by your doctor. Disclaimer: The information provided here is for informational purposes only and should not be taken as medical advice. Always consult with your healthcare provider for the most accurate and up-to-date information about Lartruvo and your specific health conditions.